title: What is the standard regimen for patients with acute promyelocytic leukemia?
abstract: Modern guidelines based on a large international consensus indicate that treatment of newly diagnosed acute promyelocytic leukemia (APL) requires distinguishing at presentation low-intermediate (<10 × 10(9)/L WBC) from high-risk (>10 × 10(9)/L WBC) disease. The concomitant use of all-trans retinoic acid (ATRA) and anthracycline based chemotherapy, with inclusion of AraC in consolidation for hyperleucocytic patients, has remained the standard of care for the past two decades. The advent of arsenic trioxide (ATO) and results from a large randomized trial, have recently challenged the standard ATRA-chemotherapy approach suggesting that at least patients in the low-intermediate category may be cured without chemotherapy using the ATRA-ATO combination.
authors.affiliation: Department of Biomedicine and Prevention, University Tor Vergata, Via Montpellier 1, 00133, Rome, Italy, francesco.lo.coco@uniroma2.it.
authors.forename: Francesco
authors.initials: F
authors.lastname: Lo-Coco
authors.forename: Laura
authors.initials: L
authors.lastname: Cicconi
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D060046:Maintenance Chemotherapy / Q000379:methods; D010087:Oxides / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide
references.citation: Blood. 1999 Nov 1;94(9):3015-21
references.pmid: 10556184
references.citation: Blood. 2002 Dec 15;100(13):4298-302
references.pmid: 12393590
references.citation: J Natl Compr Canc Netw. 2013 Sep 1;11(9):1047-55
references.pmid: 24029121
references.citation: Blood. 1999 Aug 15;94(4):1192-200
references.pmid: 10438706
references.citation: Blood. 2007 Jul 1;110(1):59-66
references.pmid: 17374742
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:391-9
references.pmid: 19074116
references.citation: Blood. 2009 Feb 26;113(9):1875-91
references.pmid: 18812465
references.citation: Cancer Res. 2002 Jul 15;62(14):3893-903
references.pmid: 12124315
references.citation: Blood. 2012 Aug 23;120(8):1570-80; quiz 1752
references.pmid: 22715121
references.citation: Leukemia. 2012 Mar;26(3):433-42
references.pmid: 21904379
references.citation: Clin Cancer Res. 2009 Oct 15;15(20):6321-6
references.pmid: 19808868
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
references.pmid: 19225113
references.citation: Blood. 2008 Oct 15;112(8):3130-4
references.pmid: 18664623
references.citation: N Engl J Med. 2013 Jul 11;369(2):111-21
references.pmid: 23841729
references.citation: Blood. 1999 Jun 15;93(12):4131-43
references.pmid: 10361110
references.citation: Leukemia. 2002 Oct;16(10):1959-73
references.pmid: 12357347
references.citation: Blood. 1997 May 1;89(9):3354-60
references.pmid: 9129042
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5703-10
references.pmid: 17116939
references.citation: J Natl Cancer Inst. 1998 Jan 21;90(2):124-33
references.pmid: 9450572
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
references.pmid: 15044693
references.citation: Leukemia. 2000 Aug;14(8):1362-70
references.pmid: 10942230
references.citation: Blood. 1997 Aug 1;90(3):1014-21
references.pmid: 9242531
references.citation: Blood. 2011 May 5;117(18):4716-25
references.pmid: 21385856
references.citation: Blood. 2004 Feb 15;103(4):1237-43
references.pmid: 14576047
references.citation: Blood. 2010 Oct 28;116(17):3171-9
references.pmid: 20644121
references.citation: Blood. 2010 Nov 11;116(19):3751-7
references.pmid: 20705755
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1047-53
references.pmid: 20085935
references.citation: N Engl J Med. 1997 Oct 9;337(15):1021-8
references.pmid: 9321529
references.citation: Blood. 2000 Aug 15;96(4):1247-53
references.pmid: 10942364
references.citation: Blood. 2008 Mar 1;111(5):2505-15
references.pmid: 18299451
references.citation: J Clin Oncol. 2011 Feb 10;29(5):495-503
references.pmid: 21220600
references.citation: Leukemia. 2013 Apr;27(4):843-51
references.pmid: 23222369
references.citation: Clin Adv Hematol Oncol. 2011 Feb;9(2):1-16
references.pmid: 22379665
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3852-60
references.pmid: 11559723
references.citation: Blood. 2006 Apr 1;107(7):2627-32
references.pmid: 16352810
references.citation: Science. 2010 Apr 9;328(5975):240-3
references.pmid: 20378816
references.citation: Blood. 2005 Apr 15;105(8):3019-25
references.pmid: 15604216
references.citation: Expert Opin Pharmacother. 2012 May;13(7):1031-43
references.pmid: 22468778
references.citation: J Clin Oncol. 2009 Feb 1;27(4):504-10
references.pmid: 19075265
references.citation: Blood. 2006 May 1;107(9):3469-73
references.pmid: 16373661
references.citation: Ann Oncol. 2006 Jan;17(1):131-4
references.pmid: 16227315
references.citation: Br J Haematol. 2003 Jan;120(2):266-70
references.pmid: 12542484
references.citation: J Clin Oncol. 2013 Nov 20;31(33):4215-21
references.pmid: 24127444